Direct Antivirals Can Achieve a Cure in All Patients With Chronic Hepatitis C due to Genotype 5: A French Multicentre Study

IF 6 2区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Liver International Pub Date : 2024-11-12 DOI:10.1111/liv.16158

Carine Nicolas, Quentin Domas, Stanislas Pol, Edouard Bardou-Jacquet, Véronique Loustaud-Ratti, Sophie Métivier, Tarik Asselah, Dominique Thabut, Marc Bourlière, Philippe Mathurin, Juliette Foucher, Dominique Larrey, Anne Varaut, Laurent Alric, François Bailly, Léon Muti, Benjamin Buchard, Armando Abergel

{"title":"Direct Antivirals Can Achieve a Cure in All Patients With Chronic Hepatitis C due to Genotype 5: A French Multicentre Study","authors":"Carine Nicolas, Quentin Domas, Stanislas Pol, Edouard Bardou-Jacquet, Véronique Loustaud-Ratti, Sophie Métivier, Tarik Asselah, Dominique Thabut, Marc Bourlière, Philippe Mathurin, Juliette Foucher, Dominique Larrey, Anne Varaut, Laurent Alric, François Bailly, Léon Muti, Benjamin Buchard, Armando Abergel","doi":"10.1111/liv.16158","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Hepatitis C virus genotype 5 (HCV-GT-5) is found mainly in South Africa. In our area in central France, the prevalence of HCV-GT-5 is 14%.</p>\n </section>\n \n <section>\n \n <h3> Methods and Results</h3>\n \n <p>Here we evaluated sustained virological response at week 12 post-treatment (SVR12) in 147 HCV-GT-5 patients from 14 French university hospitals (2014–2021) treated with direct-acting antivirals (DAA) in real-life. Patients had mainly received sofosbuvir/ledipasvir ± ribavirin, sofosbuvir/velpatasvir, and glecaprevir/pibrentasvir. Overall SVR12 was 98% (144/147). Two patients experienced relapse: one was successfully retreated with the same DAAs (sofosbuvir/ledipasvir) plus ribavirin, and the other refused further DAA treatment. One patient with virological failure (sofosbuvir/velpatasvir) had received a second treatment (sofosbuvir/velpatasvir/voxilaprevir) and progressed to cure.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>HCV-GT-5 patients treated with a DAA regimen had a 99% SVR12 in intention-to-treat (including initial therapy and retreatment) and 100% SVR12 per protocol. Sofosbuvir/ledipasvir, sofosbuvir/velpatasvir, and glecaprevir/pibrentasvir show very good efficacy in real-world HCV-GT-5 patients.</p>\n </section>\n </div>","PeriodicalId":18101,"journal":{"name":"Liver International","volume":"45 4","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver International","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/liv.16158","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Hepatitis C virus genotype 5 (HCV-GT-5) is found mainly in South Africa. In our area in central France, the prevalence of HCV-GT-5 is 14%.

Methods and Results

Here we evaluated sustained virological response at week 12 post-treatment (SVR12) in 147 HCV-GT-5 patients from 14 French university hospitals (2014–2021) treated with direct-acting antivirals (DAA) in real-life. Patients had mainly received sofosbuvir/ledipasvir ± ribavirin, sofosbuvir/velpatasvir, and glecaprevir/pibrentasvir. Overall SVR12 was 98% (144/147). Two patients experienced relapse: one was successfully retreated with the same DAAs (sofosbuvir/ledipasvir) plus ribavirin, and the other refused further DAA treatment. One patient with virological failure (sofosbuvir/velpatasvir) had received a second treatment (sofosbuvir/velpatasvir/voxilaprevir) and progressed to cure.

Conclusions

HCV-GT-5 patients treated with a DAA regimen had a 99% SVR12 in intention-to-treat (including initial therapy and retreatment) and 100% SVR12 per protocol. Sofosbuvir/ledipasvir, sofosbuvir/velpatasvir, and glecaprevir/pibrentasvir show very good efficacy in real-world HCV-GT-5 patients.

查看原文本刊更多论文

直接抗病毒药物可治愈所有基因型 5 型慢性丙型肝炎患者：一项法国多中心研究。

背景：丙型肝炎病毒基因5型（HCV-GT-5）主要出现在南非。在我们所在的法国中部地区，HCV-GT-5 的发病率为 14%：在此，我们对来自法国 14 家大学医院（2014-2021 年）的 147 名接受直接作用抗病毒药物（DAA）治疗的 HCV-GT-5 患者在治疗后第 12 周的持续病毒学应答（SVR12）进行了实际评估。患者主要接受了索非布韦/ledipasvir±利巴韦林、索非布韦/韦帕他韦和格列卡普瑞韦/pibrentasvir治疗。总体 SVR12 为 98%（144/147）。有两名患者复发：其中一名成功接受了相同的 DAA（索非布韦/雷迪帕韦）加利巴韦林治疗，另一名拒绝继续接受 DAA 治疗。一名病毒学治疗失败（索非布韦/韦帕他韦）的患者接受了第二次治疗（索非布韦/韦帕他韦/沃西普瑞韦），并取得了治愈进展：结论：接受DAA方案治疗的HCV-GT-5患者的意向治疗（包括初始治疗和再治疗）SVR12为99%，按方案治疗的SVR12为100%。索非布韦/ledipasvir、索非布韦/韦帕他韦和格列卡普瑞韦/pibrentasvir在现实世界的HCV-GT-5患者中显示出非常好的疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Liver International 医学-胃肠肝病学

CiteScore

13.90

自引率

4.50%

发文量

348

审稿时长

2 months

期刊介绍： Liver International promotes all aspects of the science of hepatology from basic research to applied clinical studies. Providing an international forum for the publication of high-quality original research in hepatology, it is an essential resource for everyone working on normal and abnormal structure and function in the liver and its constituent cells, including clinicians and basic scientists involved in the multi-disciplinary field of hepatology. The journal welcomes articles from all fields of hepatology, which may be published as original articles, brief definitive reports, reviews, mini-reviews, images in hepatology and letters to the Editor.